Bemcentinib is an experimental oral small molecule that acts as an inhibitor of AXL kinase. It is being investigated in Phase II clinical trials for various solid and hematological tumors, both as monotherapy and in combination with other treatments.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Bemcentinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Gimeracil
pharmaceutical raw material
Hydrocortisone EP Impurity I
pharmaceutical raw material
Bromotheophylline
pharmaceutical raw material
Lacidipine
pharmaceutical raw material
The international HS code for Bemcentinib (CAS 1037624-75-1) is 2933.99.
2933.99
2933 99 80
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
1-(3,4-diazatricyclo[9.4.0.02,7]pentadeca-1(15),2,4,6,11,13-hexaen-5-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine
KXMZDGSRSGHMMK-VWLOTQADSA-N
C1CCN(C1)[C@H]2CCC3=C(CC2)C=C(C=C3)NC4=NN(C(=N4)N)C5=NN=C6C(=C5)CCCC7=CC=CC=C76
Sourcing Bemcentinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.